Navigation Links
Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
Date:10/16/2008

TEMPE, Ariz., Oct. 16 /PRNewswire/ -- A team of researchers from Intrinsic Bioprobes Inc. has reported on a novel quantitative mass spectrometry immunoassay for the detection of bioactive B-type natriuretic peptide (BNP), in an article published online on Oct. 14 in the journal of Circulation: Heart Failure. In collaboration with colleagues from Scios Inc. in Fremont, Christ Hospital in Cincinnati, and Medivation Inc. in San Francisco, the team discovered very low concentration of bioactive BNP in plasma obtained from patients with heart failure, and presented direct structural evidence for several proteolytically degraded forms of BNP in these patients.

"Commercially available assays for immunoreactive BNP do not reflect the bioactivity of the natriuretic peptide system, since they measure both unprocessed, inactive proBNP and mature BNP 1-32," says Eric Niederkofler, Ph.D., the principal investigator from Intrinsic Bioprobes. BNP is synthesized as a 108 amino acid propeptide and proteolytically processed to release an inactive 76 amino acid N-terminal fragment and bioactive mature BNP 1-32 into the bloodstream. "This is the first assay capable of detecting and quantifying BNP 1-32 alone. Furthermore, the assay allowed us to study the molecular complexity of BNP degradation, revealing rapid in vitro degradation of BNP 1-32, and necessitating certain preservation protocol during blood collection and subsequent sample handling," adds Niederkofler.

"This work is going to add greater clarity to how clinicians and researchers approach natriuretic peptides and heart failure," says Dr. Roger Mills, from Ortho McNeil Jannsen Scientific Affairs. "The results may provide an explanation for the 'natriuretic paradox' of increased natriuretic hormone levels with blunted effects in heart failure patients."

Intrinsic Bioprobes Inc. is a privately held Biotechnology Company focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis. The company's proprietary technologies consist of Mass Spectrometric Immunoassay (MSIA), a high-performance immunoassay combining micro-scale immunoaffinity capture and mass spectrometry for high throughput analysis of proteins from complex biological matrices, and Bioreactive Mass Spectrometer Probes (BRP), devices for rapid, sensitive and accurate protein characterization. These root technologies are incorporated into the MASSAY System, a high throughput mass spectrometry platform for rapid proteome analysis. For more information about Intrinsic Bioprobes Inc., please visit http://www.intrinsicbio.com.

Contact:

Intrinsic Bioprobes Inc.

Monte Cain, Director of Business Development

Tel.: (480) 804-1778

E-mail: monte@intrinsicbio.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Intrinsic Bioprobes Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
2. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
3. Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System
4. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
5. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
6. UC Riverside researcher develops novel method to grow human embryonic stem cells
7. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
8. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
9. Tree branching key to efficient flow in nature and novel materials
10. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
11. GEN Reports on Novel Hit-to-Lead Drug Discovery Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... ... taking over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding ... know someone who suffers from hay fever, urticaria, asthma, atopic eczema or a ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... clients throughout the biopharma and life sciences industries, continue to be in demand ... Tunnell’s Kip Wolf will be speaking on “The State of Information Governance in ...
(Date:6/22/2017)... ... June 22, 2017 , ... Charm Sciences, Inc. is pleased ... test was determined to be appropriate as a screening test at dairies and farms ... Charm EZ system, and the Charm EZ Lite system. These systems are a combination ...
(Date:6/20/2017)... ... June 20, 2017 , ... HorizonScan is ... which pose the most likely threat to their products at the annual IFT ... , IFT's annual food expo attracts over 20,000 attendees representing food science professionals ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):